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MRIFrontotemporal dementia (FTD) is the second commonest young-onset neurodegenerative dementia. The
canonical clinical syndromes are a behavioural variant (bvFTD) and two language variants (progressive
nonﬂuent aphasia, PNFA, and semantic dementia, SD) although there is overlap with motor neurone disease
and the atypical parkinsonian disorders corticobasal syndrome (CBS) and progressive supranuclear palsy
syndrome (PSPS). Characteristic patterns of atrophy or hypometabolism are described in each of the variants
but in reality imaging studies are rather heterogeneous. This review attempts to address four key questions in
the neuroimaging of FTD: 1) what are the early imaging features of the different FTD syndromes (and how do
these change as the disease progresses); 2) what do studies of presymptomatic genetic cases of FTD tell us
about the very early stages of the disease; 3) can neuroimaging help to differentiate the different FTD
syndromes; and 4) can neuroimaging help to differentiate FTD from other neurodegenerative diseases? This
article is part of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.: Imaging Brain Aging and
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Frontotemporal dementia (FTD) is a neurodegenerative disorder
associated with atrophy of the frontal and temporal lobes. Clinically, a
number of overlapping clinical syndromes are seen, with the most
common being a behavioural variant (bvFTD) and two language
variants (progressive nonﬂuent aphasia, PNFA, and semantic dementia,
SD) which are often collectively called primary progressive aphasia
(PPA).Motor neuronediseasemayoccur in associationwith anyof these
(when it is knownasFTD-MND), althoughusuallywithbvFTD.Although
one of these clinical syndromes may predominate at the onset of the
illness there is substantial overlap as the disease progresses, including
with the atypical parkinsonian disorders, corticobasal syndrome (CBS)
and progressive supranuclear palsy syndrome (PSPS) [1–3].
FTD is genetically and pathologically heterogeneous without a
clear relationship between the clinical phenotype and the underlying
pathogenetics (Fig. 1). Up to a third of patients with FTD will have an
autosomal dominant family history of the disease with studies
suggesting that bvFTD is more heritable than the language variants
[4]. Mutations in six genes have been associated with genetic FTD
although only two of these, progranulin (GRN) and microtubule-
associated protein tau (MAPT), are common causes, each accounting
for around 5–10% of all FTD patients [4]. Clinically, MAPT mutations
are usually associated with bvFTD although CBS and more rarely PSPShave been described. GRN mutations are also associated with bvFTD
and CBS but, unlike MAPT mutations, a PPA syndrome can also occur.
The clinical phenotypes caused by mutations in the other four genes
(valosin-containing protein, VCP, transactive response DNA-binding
protein, TARDP, fused-in-sarcoma, FUS, charged multivesicular body
protein 2B, CHMP2B) are variable including bvFTD, FTD-MND and for
VCPmutations a speciﬁc association with inclusion body myositis and
Paget's disease of the bone (known as IBMPFD).
FTD clinical syndromes are usually associated with one of the
frontotemporal lobar degeneration (FTLD) pathologies. Until recently
two major pathological types of FTLD were described, those with tau-
positive pathology (FTLD-tau) and those with tau-negative, ubiquitin-
positive pathology (FTLD-U). However it has been shown that FTLD-U
actually consists of three separate groups: those with TDP-43-positive
pathology (FTLD-TDP), thosewith FUS-positive pathology (FTLD-FUS)
and a minority of cases which are both TDP-43 and FUS-negative
(now called FTLD-UPS). Each of these major pathological types also
has a number of subtypes [5,6]:
• FTLD-tau comprises cases of corticobasal degeneration (CBD), progres-
sive supranuclear palsy (PSP), Pick's disease (PiD), argyrophilic grain
disease (AGD), multiple system tauopathywith dementia (MSTD) and
the pathology associated with mutations in theMAPT gene.
• FTLD-TDP has a number of pathologically distinct subtypes based on
the pattern and location of protein accumulation (types A, B, C and
D) and includes patients with GRN, VCP and TARDP mutations.
• FTLD-FUS subtypes include atypical FTLD with ubiquitin-inclusions
(aFTLD-U), neuronal intermediate ﬁlament inclusion disease
(NIFID), and basophilic inclusion body disease (BIBD).
• FTLD-UPS cases are a very small minority but include the patients
with CHMP2B mutations.
Fig. 1. The clinical, genetic and pathological heterogeneity of frontotemporal dementia. Legend: corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), argyrophilic grain
disease (AGD), multiple system tauopathywith dementia (MSTD), GRN (progranulin), TARDP (transactive response DNA-binding protein), VCP (valosin-containing protein), atypical FTLD
with ubiquitin-inclusions (aFTLD-U), neuronal intermediateﬁlament inclusion disease (NIFID), basophilic inclusion bodydisease (BIBD), CHMP2B (chargedmultivesicular bodyprotein 2B).
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pathology e.g. in one study it was seen in 7% of bvFTD cases and 10% of SD
cases [7].
From a neuroimaging perspective, FTD is classically associated with
frontal and temporal lobe atrophy with sparing of posterior cortical areas
[3]. BvFTD is most commonly described as having asymmetrical (often
right-sided predominant) fronto-temporal atrophy whilst the language
variants are said to have speciﬁc imaging patterns of asymmetrical
anteroinferior temporal lobe involvement in SD and asymmetrical left-
sided predominant inferior frontal lobe and insula involvement in PNFA
[8–10] (Fig. 2). However, in reality there ismuchheterogeneitywithin the
FTD neuroimaging literature. This is likely to reﬂect a number of different
issues, including the variability within a particular clinical phenotype, the
fact that patients are being studied at different stages of a progressive
illness and that different pathological causes of the same clinical
phenotype may affect distinct (although overlapping) brain networks.
With these factors in mind, this review attempts to address a number of
key questions in the neuroimaging of FTD:
1) What are the early imaging features of the different FTD
syndromes (and how do these change as the disease progresses)?
2) What do studies of presymptomatic genetic cases of FTD tell us
about the very early stages of the disease?
3) Can neuroimaging help to differentiate the different FTD syn-
dromes (either clinically or pathologically)?
4) Can neuroimaging help to differentiate FTD from other neurode-
generative diseases?
2. What are the early imaging features of the different FTD
syndromes (and how do these change as the disease progresses)?
2.1. Behavioural variant frontotemporal dementia
BvFTD is characterized by a change in personality and progressive
impairment of behaviour. Symptoms include disinhibition, apathy, loss
of empathy, obsessive–compulsive behaviour and a change in appetite,particularly the development of a sweet tooth [3]. However early in the
disease symptoms may be subtle and can be mistaken for psychiatric
problems suchasdepression, or evendismissed completely. At this early
stage diagnosis can therefore be difﬁcult and neuroimaging can be
helpful in supporting a positive diagnosis of bvFTD.
A meta-analysis of neuroimaging studies in bvFTD identiﬁed a
network of (mostly right hemisphere) areas including parts of the
frontal lobe (anterior medial frontal, gyrus rectus and superior
frontal) as well as anterior cingulate, anterior insula and thalamus
[8,9]. However, this study did not attempt to separate patients by
severity or stage of the disease — mean MMSE in the included studies
varied between 14 and 25, withmean disease duration between 2 and
4 years [8,9]. One study that attempted to look at patients at different
stages of bvFTD separated them into three groups according to their
Clinical Dementia Rating (CDR), an early group with CDR 0.5 and two
other groups with CDR 1 and CDR2-3 [11]. In the early group atrophy
involved areas in the frontal lobe (rostromedial frontal, frontal pole,
dorsolateral frontal and orbitofrontal) as well as anterior cingulate,
anterior insula, hippocampus and subcortical areas (ventral striatum
and dorsomedial thalamus). Atrophy was bilateral but right hemi-
sphere involvement was greater than left. With greater CDR score
atrophy becamemore extensive in the same areas, particularly within
the frontal lobe, with spread to more posterior areas including
posterior insula, temporal and anterior parietal lobes [11]. A further
study of pathologically-conﬁrmed bvFTD patients separated by CDR
found very similar results [12]. Further studies have suggested that
these areas affected in early disease (frontal-insula-anterior cingu-
late) are part of a structurally and functionally connected neural
network (a ‘salience network’) that is particularly vulnerable in bvFTD
and that has a histopathological correlate in the form of von Economo
neurons [13–15]. In one resting-state fMRI study loss of right
frontoinsular salience network connectivity correlated with bvFTD
disease severity [16].
However, bvFTD is pathologically heterogeneous and it is unclear
whether this same “salience network” is affected in all groups
independent of the underlying pathology. One recent study
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divided into four separate neuroanatomical groups: frontal-dominant,
temporal-dominant, frontotemporal and temporofrontoparietal [17].
In a subgroup of patients in this study who had come to post-mortem
there were no clear correlations between imaging features and
pathological subtype apart from the temporal-dominant group who
all had mutations in MAPT[17]. Further work needs to be done to see
whether these four groups map on to separate brain networks (or
subsystems within the same network).
Although atrophy is commonly seen at an early stage in bvFTD
there are a number of patients who have been given the diagnosis on a
clinical basis but who have normal scans at presentation — recently it
has been suggested that many (if not most) of these patients have a
‘benign’ or ‘nonprogressive’ form of bvFTD [18–22]. These patients are
difﬁcult to distinguish from typical progressive bvFTD on the basis ofFig. 2. Examples of structural MR imaging in pathologically-conﬁrmed frontotemporal demen
bvFTD (A FTLD-tau Pick's disease, B FTLD-tauMAPTmutation, C FTLD-TDP type A with GRNm
G GRN mutation) and LPA (H Alzheimer's disease).clinical symptoms but they have no supportive imaging abnormalities
including having normal FDG-PET imaging as well [20].2.2. Semantic dementia
SD is probably the most homogeneous of the FTD syndromes with
characteristic clinical and neuroimaging features, and a clear
correlation with FTLD-TDP type C pathology. Clinically, patients
present with ﬂuent aphasia, anomia, single word comprehension
difﬁculties and a surface dyslexia secondary to a verbal semantic
impairment. Visual, auditory, olfactory and gustatory semantic
impairment can develop later on in the disease. Behavioural
symptoms similar to bvFTD may be present, occurring later in the
disease process in those with left hemisphere predominant atrophytia syndromes. Legend: Images each show coronal (top) and axial (bottom) sections for
utation, D FTLD-FUS aFTLDU), SD (E FTLD-TDP type C), PNFA (F FTLD-tau Pick's disease,
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(where it may be the presenting feature) [23].
Asymmetrical atrophy or hypometabolism of the temporal lobes is
seen in most cases, predominantly affecting the anterior and inferior
aspects of the temporal lobes, in particular the temporal pole, perirhinal
cortex and anterior fusiform gyrus but also the hippocampus and
amygdala, with relative sparing of the superior temporal gyrus [23–25]
(Fig. 2D). In the most common variant there is left greater than right
temporal lobe atrophy, with the opposite pattern seen less frequently.
Patients are usually a number of years into their illness before they
present and hence few studies have looked at the very early changes in
the disease. One single case study followed a patient with SD from a very
early period when there was only very subtle atrophy of the left anterior
temporal lobe [26]. Over a follow up of 8 years there was increasing left
temporal atrophy with subsequent atrophy of homologous right
temporal areas. A larger study using cortical thickness measures
separated patients with SD into three groups based on the severity of
their anomia [27]: in the least affectedgroupcortical thinningwas limited
to the anterior and inferior parts of the left temporal lobe as well as a
small area of thinning in the very anterior part of the right temporal lobe
affected. In themore severely affected groups therewas spread to involve
more posterior and superior parts of the left temporal lobe, parts of the
left frontal lobe (orbitofrontal and inferior gyri), the insula and anterior
cingulate. Therewas also increasing involvement of homologous areas in
the right temporal lobe, initially affecting the anterior and inferior parts
but spreading more posteriorly and superiorly in the most severely
affected group. This study looked only at patients with initial left-sided
predominant atrophy but studies of patients with right-sided predom-
inant involvement suggest that a comparable mirror-image pattern of
atrophy is seen both initially and with disease progression [28,29].2.3. Progressive nonﬂuent aphasia
PNFA presents with speech production impairment secondary to
agrammatism and apraxia of speech [1]. Other features include
phonemic errors, anomia and sentence comprehension impairment. It
is more clinically heterogeneous than SD and there are some
suggestions that there are further clinical subtypes of PNFA e.g.
cases with only agrammatism or apraxia of speech, or with a
prominent anomia [30,31]. Pathologically, patients with prominent
apraxia of speech often have tau pathology and may have an
associated CBS or PSPS [32–34]. In contrast, patients with GRN
mutations (and therefore FTLD-TDP type A pathology) generally do
not have an apraxia of speech [31]. Of note, a third variant of PPA
(distinguishable from SD and PNFA) called logopenic aphasia (LPA)
has been described in recent years although this is mostly caused by
Alzheimer's pathology rather than an FTLD pathology. Patients with
LPA present with impaired word retrieval and sentence repetition
with intact motor speech and grammar [1,35].
Neuroanatomically, the left inferior frontal lobe, insula and
premotor cortex have been shown in a number of studies to be the
key areas affected in early PNFA [8,14,27,32,35,36]. A single case study
that followed a patient with PNFA over 4 years as she developed an
associated CBS showed subsequent involvement of other areas in the
frontal lobe, as well as the temporal lobe, anterior parietal lobe and
subcortical structures (caudate and thalamus) [37]. The same cortical
thickness study discussed above for SD also studied PNFA in a similar
way, splitting patients into three groups by severity of anomia [27]: in
the least affected group the areas involved were the left inferior
frontal lobe, insula and premotor cortex, whilst in the more affected
groups there were middle and superior frontal, superior and lateral
temporal, and anterior parietal cortical thinning. Similar ﬁndingswere
seen in a study examining change in cortical thickness over 2 years in
PNFA although with less superior temporal lobe involvement seen in
this cohort as the disease progressed [38].LPA is associated with asymmetrical left-sided predominant
atrophy affecting particularly the posterior superior temporal and
inferior parietal lobes aswell as the posterior cingulate, precuneus and
medial temporal lobe [35,39,40]. One retrospective cortical thickness
study looked at a group of patients with PPA and Alzheimer's
pathology all with a probable LPA syndrome and separated the
patients into two groups according to severity of anomia [41]: in the
less severe group the pattern of atrophy was restricted to the areas
discussed above but in themore severely affected group therewas also
cortical thinning in more anterior left temporal lobe areas, including
the superior and middle temporal gyri, as well as the left inferior
frontal lobewith involvement of homologous areas to those seen in the
less severely affected cases in the right hemisphere (i.e. the temporo-
parietal junction, posterior cingulate, precuneus and medial temporal
lobe). Similar results were found in a recent longitudinal study of
cortical thickness with involvement of more anterior temporal lobe
areas, inferior frontal lobe and dorsolateral frontal cortex in the left
hemisphere as the disease progressed [38].
One outstanding question in the study of patients with a nonﬂuent
aphasia is whether the pattern of atrophy differs between those with
different pathologies, particularly between those with tau pathology
and TDP-43 pathology (including GRN mutations). This has yet to be
clearly addressed but one small study showed more widespread
asymmetrical left-sided predominant fronto-temporo-parietal atrophy
affecting both the dorsal and ventral language networks in patientswith
GRNmutations in comparison to other PNFA (and LPA) patients [40].2.4. Frontotemporal dementia with motor neurone disease/amyotrophic
lateral sclerosis
FTD-MND can present initially with either an FTD syndrome
(usually bvFTD, less commonly PNFA and very rarely SD) or with an
MND syndrome. If it presents as bvFTD the behavioural symptoms are
essentially indistinguishable from patients who do not develop MND
although delusions appear more common in FTD-MND [42]. Patho-
logically, FTD-MND is almost always FTLD-TDP (either type B or less
commonly type A) but rarely can be FTLD-FUS [28,43]. Familial FTD-
MND is associated with a locus on chromosome 9 [44,45], although
rare cases of patients with GRN mutations have been described [46].
There have been limited neuroimaging studies of patients with
FTD-MND/FTD-ALS. Some cases have been described with atrophy
or hypometabolism limited to the anteromedial temporal lobes in
the early stages [47,48] whilst other studies have shown more
frontal lobe involvement particularly in motor and premotor areas
[43,49].2.5. Corticobasal syndrome
CBS commonly presents with cortical (limb apraxia, cortical sensory
loss, myoclonus) and extrapyramidal (asymmetrical akinetic-rigid
syndrome) dysfunction. It can be associated with cognitive impairment
(often executive dysfunction), language problems (usually PNFA)
and/or behavioural symptoms [33,50,51]. Pathologically, CBS can be
associated with FTLD-tau (CBD or PSP), FTLD-TDP (usually type A
including GRNmutations) and also with Alzheimer's pathology [52,53].
CBS has traditionally been associated with asymmetrical (usually
left greater than right) frontoparietal and insula atrophy [14,54].
Recent studies have compared the neuroimaging features of CBS
caused by different pathologies [53,55,56]: atrophy was predomi-
nantly frontal in CBD and PSP pathologies but more widespread
within the hemisphere in FTLD-TDP and Alzheimer's pathology,
overlapping in all groups in the posterior frontal lobe (premotor and
supplementary motor areas) and the insula. More parietal atrophy
was seen in Alzheimer's pathology than in the other pathologies.
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about the very early stages of the disease?
Most imaging studies of genetic FTD have investigated symptom-
atic patients with MAPT and GRN mutations — these suggest differing
patterns of atrophy with asymmetrical fronto-temporo-parietal
atrophy in GRN mutations and focal (often relatively symmetrical)
temporal lobe atrophy in MAPT mutations [57,58]. A small study has
also suggested differences between different MAPT mutations, with
more medial temporal lobe atrophy in those mutations that affect the
alternative splicing of tau pre-messenger RNA, and more lateral
temporal lobe atrophy in those mutations that affect the structure of
the tau protein [59]. Patterns of atrophy are less clear in patients with
mutations in the genes that are only rare causes of FTD i.e. FUS, TARDP,
CHMP2B and VCP. One case series of a chromosome 9p-linked FTD-
MND family showed bilateral frontal lobe involvement with sparing of
the temporal lobes in individual cases [44].
Studying genetic FTD offers the opportunity to identify the very
earliest imaging features by investigating pre-symptomatic patients
who are ‘at-risk’ of developing FTD. However, only a few studies have
so far been published that have done this. Two case reports that have
followed patients from a presymptomatic period through to symptom
onset have identiﬁed that cell loss occurs a number of years prior to
the onset of symptoms: a patient with a GRN mutation and a PPA
syndrome was shown to have asymmetrical atrophy at least
18 months prior to the onset of symptoms with left-sided fronto-
temporo-parietal atrophy particularly affecting superior frontal and
frontopolar regions, anterior cingulate, inferior temporal, middle
temporal and fusiform gyri as well as the angular gyrus [60]; whilst a
patient with familial FTLD-U (later shown to be FTLD-TDP type A but
without a GRN mutation) and a PPA syndrome was shown to have
very focal left frontal lobe atrophy affecting the pars opercularis
around 2 years prior to the onset of symptoms [61]. Larger group
studies have also been performed using a variety of imaging
techniques [62–65]. A study of four pre-symptomatic GRN mutation
carriers (in a family with a PPA clinical syndrome) showed atrophy
and hypometabolism in left frontal (inferior, middle and superior),
left middle temporal and left parietal lobes compared to controls. A
diffusion tensor imaging (DTI) study showed abnormalities in
presymptomatic GRN carriers in the left uncinate fasciculus and in
the left inferior occipitofrontal fasciculus although with no difference
from controls in a volumetric imaging analysis (voxel-based mor-
phometry of grey and white matter) [63]. Fewer studies have been
performed in MAPT mutation carriers but one small study of three
patients showed presymptomatic hippocampal atrophy in two
patients and dopaminergic dysfunction (using PET imaging) in all
three. [62]. A larger study with fourteen presymptomatic MAPT
mutation carriers showed proton MRS abnormalities several years
before the onset of symptoms [65].4. Can neuroimaging help to differentiate the different FTD
syndromes (either clinically or pathologically)?
Few studies have compared the different FTD clinical syndromes
[8]. One study using volumetric imaging and deﬁned regions of
interest compared FTD, SD and PNFA [66]: each of the syndromes
could be discriminated from each other with relatively high
sensitivity and speciﬁcity: FTD v SD (sensitivity 100%, speciﬁcity
100%), FTD v PNFA (sensitivity 92%, speciﬁcity 89%) and SD v PNFA
(sensitivity 86%, speciﬁcity 100%). SD and PNFA have also been
compared with LPA, using an automated structural MRI-based
classiﬁcation method (support vector machines) [67]. As with the
ﬁrst study discrimination of SD from other syndromes had a high
speciﬁcity (although lower sensitivity) whilst discrimination between
the non-SD syndromes was not as accurate: SD v PNFA (sensitivity84%, speciﬁcity 94%), PNFA v LPA (sensitivity 81%, speciﬁcity 91%) and
SD v LPA (sensitivity 94%, speciﬁcity 94%) [67].
More importantly than separating FTD patients by their clinical
phenotype perhaps will be the ability to separate patients by their
underlying pathology, particularly as trials of targeted disease-modify-
ing agents are developed over the next few years: unless there is a
reliable and objectiveway of identifying patients in this way, such trials
risk including patients with several different pathologies — this both
reduces the chance of detecting a positive outcome and risks exposing
individualswhowill not beneﬁt from treatment to potential side effects.
In early studies there were conﬂicting results, with some showing
differences between patientswith FTLD-tau and FTLD-U [68] and others
showing very similar patterns of atrophy [69]. However, as the
pathological basis of FTLD has become increasingly stratiﬁed with the
descriptions of FTLD-TDP and FTLD-FUS (and their subtypes) more
recent studies have suggested speciﬁc differentiating patterns of
atrophy. Two studies of FTLD-TDP subtypes showed very similar
ﬁndings (although confusingly used separate numbering systems for
TDP-43 pathology in the two papers) [28,43]. Using the recently
described harmonised classiﬁcation system for TDP-43 pathology [70],
type A patients had an asymmetrical pattern of atrophy with frontal,
temporal and parietal lobe as well as caudate involvement, type B
patients had medial posterior frontal, insula and medial temporal lobe
atrophy, and type C patients had asymmetrical anteroinferior temporal
lobe atrophy with involvement of the insula (i.e. the pattern seen in
patients with SD). Recent investigations of patients with FTLD-FUS
pathology have shown involvement of the frontal-insula-anterior
cingulate network but with particularly severe caudate atrophy
compared to other FTD patients [71–73]. Whilst these studies were
limited to a single type of abnormal protein inclusion (TDP-43 or FUS)
one recent study has investigated imaging across FTLD-tau, FTLD-TDP
and FTLD-FUS subtypes [74]. It suggests that the different FTLD
pathologies are not speciﬁc for a particular brain region but rather
that they target distributed brain networks in a predictable manner,
segregating according to two factors: ﬁrstly, whether they show
relatively symmetric versus strongly asymmetric hemispheric atrophy,
and, secondly, whether they are associated with relatively localised
temporal versus extra-temporal atrophywithin anaffectedhemisphere.
Patterns of atrophy seen in the studywere: asymmetric, predominantly
temporal lobe atrophy in TDP-C, relatively symmetric, predominantly
temporal lobe atrophy in MAPT mutations, strongly asymmetric,
distributed atrophy in PiD and TDP-A, and relatively symmetric,
predominantly extratemporal atrophy in CBD and FUS [74]. However,
although there are suggestive group differences in neuroimaging
patterns between the pathological subtypes neither this study nor any
of the other studies have quantiﬁed the speciﬁcity and sensitivity for
distinguishing the different syndromes. Furthermore, it has yet to be
shown whether particular imaging features described in the different
pathologies (or clinical syndromes) at a group level can usefully
translate into a way of diagnosing patients on a single case basis: the
answer to this question is likely to require larger collaborative studies
(each of the currently published studies reporting only relatively small
numbers of cases).
5. Can neuroimaging help to differentiate FTD from other
neurodegenerative diseases?
Clinically, FTD is usually clearly distinguishable from the typical
amnestic Alzheimer's disease (AD) presentation. However, there can
be a grey area with some FTD patients having prominent impairment
of episodic memory and some patients with AD having more atypical
presentations i.e. language variant AD (usually logopenic aphasia),
frontal variant AD (i.e. a syndrome with prominent behavioural
symptoms and/or executive dysfunction), posterior cortical atrophy
(which often presents with visuospatial and/or visuoperceptual
impairment and is therefore sometimes called the ‘visual variant’)
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studies comparing FTD and AD it is therefore important to understand
the groups being studied i.e. whether they are clinical or pathological
phenotypes.
Studies comparing FTD with a typical AD syndrome have shown
differences using voxel-basedmorphometry of structural MRI (atrophy
in posterior parietal and occipital cortex in AD compared to atrophy in
frontal insula-cingulate and striatum in FTD [75]), cortical thickness
(greater parietal and precuneus thinning in AD [76]), amyloid PET
imaging (positive in AD [77]), ASL (hypoperfusion in parietal regions
and posterior cingulate in AD compared to hypoperfusion in the frontal
lobes in FTD [78,79]), DTI (reduced fractional anisotrophy in frontal
brain regions in FTD [80]) and combined FDG-PET with structural MRI
[81]. Automated methods of classiﬁcation using support vector
machines have shown the ability to accurately differentiate AD and
FTD with relatively high sensitivity and speciﬁcity [82,83].
Studies investigating more atypical phenotypes of AD have
suggested that, independent of clinical phenotype, patients with
underlying AD pathology have involvement of posterior cingulate,
precuneus, posterior parietal and medial temporal areas [84,85].
Comparison of PPA patients with and without AD pathology suggests
that differentiating factors between these two groups include greater
left temporo-parietal atrophy in those with AD pathology (usually an
LPA syndrome clinically) and the presence of knife-edge anterior
temporal lobe atrophy in those with FTD pathology [86][87].
Less commonly, FTD can be mistaken for dementia with Lewy
Bodies (DLB) — this may well be because some patients with FTD
clinical syndromes can develop delusions and/or visual hallucinations
[42,88]. One small study suggested that MRI was not helpful in
differentiating FTD from DLB [89]. However a recent study has shown
accurate differentiation using 123I-MIBG scintigraphy in which uptake
is markedly reduced in DLB but normal in FTD [90].
As with the studies that attempted to distinguish the different FTD
syndromes it is not clear that the described group differences between
FTD and AD (or FTD and DLB) can translate into an adequate diagnostic
biomarker at the single case level. Two issues in particular need to be
addressedmore thoroughly in future studies: ﬁrstly, to what extentMR
imaging adds extra diagnostic information in addition to a cognitive and
behavioural assessment for individual patients; and secondly, to what
extent ‘difﬁcult’ or ‘atypical’ clinical cases can be diagnosed accurately—
most comparative imaging studies have investigated typical AD and FTD
cases whereas on a clinical basis it is the less typical cases which prove
most difﬁcult to diagnose.
6. The future of neuroimaging in FTD
Newer imaging techniques such as DTI, ASL and resting state fMRI
(and the multimodal combination of such techniques) are likely to be
increasingly used in studies of FTD. Newer PET imaging methods have
recently been investigated (e.g. cholinergic imaging in FTD, PSP and CBS
[91] and newer 18F amyloid labelling compounds) and in the future the
development of PET ligands that would bind to tau, TDP-43 or FUS
would be a huge advance in the ability to make a molecular diagnosis
[92]. Increased international collaboration between centres will be
important in furthering our understanding of the neuroimaging of FTD,
as has happened in other neurodegenerative diseases (e.g. the
Alzheimer's Disease Neuroimaging Initiative, ADNI [93]), and in
particular for studies of presymptomatic genetic FTD and in the
development of trials of disease-modifying therapies [94].
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